A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer
Preclinical studies in small cell lung cancer (SCLC) have shown that hyaluronic acid (HA)
can be effectively used to deliver chemotherapy and selectively decrease CD44 expressing …
can be effectively used to deliver chemotherapy and selectively decrease CD44 expressing …
Treatment of relapsed small-cell lung cancer—a focus on the evolving role of topotecan
CMR Lima, A Chiappori - Lung Cancer, 2003 - Elsevier
Despite the high response rates to chemotherapy, small-cell lung cancer (SCLC) is among
the most lethal malignancies. Long-term survival is anecdotal for patients with extensive …
the most lethal malignancies. Long-term survival is anecdotal for patients with extensive …
Management of small cell lung cancer
KK Ciombor, CMS Rocha Lima - Current Treatment Options in Oncology, 2006 - Springer
Opinion statement Small cell lung cancer (SCLC) is an aggressive type of lung cancer
characterized by rapid growth and early metastasis. It is chemosensitive and radiosensitive …
characterized by rapid growth and early metastasis. It is chemosensitive and radiosensitive …
Second-line chemotherapy in recurrent small cell lung cancer: Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or …
S Sundstrøm, RM Bremnes, S Kaasa, U Aasebø… - Lung Cancer, 2005 - Elsevier
PURPOSE:: To evaluate the benefit of crossover chemotherapy with etoposide and cisplatin
(EP) versus cyclophosphamide, epirubicin, vincristine (CEV) at relapse after primary …
(EP) versus cyclophosphamide, epirubicin, vincristine (CEV) at relapse after primary …
Enhancement of in vitro and in vivo anticancer activities of polysaccharide peptide from Grifola frondosa by chemical modifications
Context: Grifola frondosa (Polyporaceae), maitake, is a widely consumed edible mushroom
in some Asian countries. The fruit bodies and mycelia of maitake have shown different …
in some Asian countries. The fruit bodies and mycelia of maitake have shown different …
Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma
FM Johnson, LM Krug, HT Tran, S Shoaf… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND Small cell lung carcinoma (SCLC) cell lines commonly express KIT and its
ligand, stem cell factor, suggesting an autocrine loop promoting cell growth. Imatinib inhibits …
ligand, stem cell factor, suggesting an autocrine loop promoting cell growth. Imatinib inhibits …
Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected
Y Takahashi, H Horio, T Hato, M Harada… - … and thoracic surgery, 2015 - academic.oup.com
OBJECTIVES Despite recent progress in diagnostic technology and therapeutic approaches
to non-small-cell lung cancer (NSCLC), 30–75% of patients develop tumour recurrence after …
to non-small-cell lung cancer (NSCLC), 30–75% of patients develop tumour recurrence after …
The role of topotecan in treating small cell lung cancer: second-line treatment
J von Pawel - Lung cancer, 2003 - Elsevier
Small-cell lung cancer (SCLC) is highly chemosensitive but up to 70% of patients with
limited disease and more than 90% of patients with extensive disease will relapse after first …
limited disease and more than 90% of patients with extensive disease will relapse after first …
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells
S Trojandt, D Knies, S Pektor, S Ritz… - Cancer Immunology …, 2013 - Springer
The camptothecin analogue topotecan (TPT) induces tumor cell apoptosis due to
interference with topoisomerase I and is clinically used as a second-line chemotherapeutic …
interference with topoisomerase I and is clinically used as a second-line chemotherapeutic …
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
W Schuette, S Nagel, S Juergens, I Bork… - Clinical lung cancer, 2005 - Elsevier
BACKGROUND: Gemcitabine and irinotecan have shown a broad range of activity in solid
tumors, including smallcell lung cancer (SCLC), with a synergistic effect on SCLC cell lines …
tumors, including smallcell lung cancer (SCLC), with a synergistic effect on SCLC cell lines …